Choriogonadotropin Alfa
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Choriogonadotropin Alfa |
| DrugBank ID | DB00097 |
| Brand Names (EU) | Ovitrelle |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 98.44% |
Approved Indication (EMA)
Ovitrelle is indicated in the treatment of: women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilisation (IVF): Ovitrelle is administered to trigger final follicular maturation and luteinisation after stimulation of follicular growth; anovulatory or oligo-ovulatory women: Ovitrelle is administered to trigger ovulation and luteinisation in anovulatory or oligo-ovulatory patients after stimulation of follicular growth.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | peptic esophagitis | 98.44% | DL |
| 2 | postural orthostatic tachycardia syndrome | 98.33% | DL |
| 3 | esophageal disease | 97.61% | DL |
| 4 | Raynaud disease | 97.43% | DL |
| 5 | non-syndromic esophageal malformation | 96.89% | DL |
| 6 | esophageal ulcer | 96.84% | DL |
| 7 | His bundle tachycardia | 95.95% | DL |
| 8 | sinoatrial block | 95.88% | DL |
| 9 | progressive familial heart block | 95.66% | DL |
| 10 | sinoatrial node disease | 95.47% | DL |
| 11 | restless legs syndrome | 95.43% | DL |
| 12 | esophageal atresia (disease) | 95.34% | DL |
| 13 | active peptic ulcer disease | 95.31% | DL |
| 14 | gastrojejunal ulcer | 95.30% | DL |
| 15 | peptic ulcer perforation | 95.30% | DL |
| 16 | migraine disorder | 95.28% | DL |
| 17 | esophageal leukoplakia (disease) | 95.23% | DL |
| 18 | acne (disease) | 95.16% | DL |
| 19 | dyskinesia of esophagus | 95.16% | DL |
| 20 | esophageal diverticulosis | 95.16% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.